Tang Xinfeng, Liu Qiwen, Cai Fangtong, Tian Hui, Shi Xincheng, Tang Suqin
Department of Psychology, Renmin University of China, Beijing, China.
Department of Sociology, Law School, Shenzhen University, Shenzhen, China.
Front Psychol. 2022 Aug 22;13:792356. doi: 10.3389/fpsyg.2022.792356. eCollection 2022.
The objective of the study is to provide a reliable estimate of the pooled prevalence of social anxiety disorder (SAD) and social anxiety symptoms (SAS) among children, adolescents, and young adults (CAYA) in China. Meta-analysis is used to provide pooled-prevalence rate of SAD and SAS. Literature searches were conducted in both English and Chinese databases from the database's inception to April 2019. Eleven studies were identified for SAD, and 17 were included for SAS. The results revealed a pooled prevalence of SAD of 2.1% (95% CI: 1.2-3.8%) with high between-studies heterogeneity ( = 1,055.2, = 99.1%, < 0.001). The pooled prevalence estimate of SAS was 23.5% (95% CI: 18.6-29.3%), also with significant heterogeneity ( = 1,019.3, = 98.4%, < 0.001). Different diagnostic tools or self-report scales reported significant different prevalence of SAD or SAS. Further analysis stratified by gender, age, sampling methods, economic status, and risk of bias were performed. Limitations include the high level of heterogeneity between studies, inadequate number of the studies, and significant differences in prevalence caused by measurements.
https://www.crd.york.ac.uk/prospero/display_record.php?ID=CRD42020149591, identifier: PROSPERO CRD42020149591.
本研究的目的是对中国儿童、青少年和青年（CAYA）社交焦虑障碍（SAD）和社交焦虑症状（SAS）的合并患病率提供可靠估计。采用荟萃分析来提供SAD和SAS的合并患病率。从数据库建立至2019年4月，在英文和中文数据库中进行了文献检索。确定了11项关于SAD的研究，17项关于SAS的研究被纳入。结果显示，SAD的合并患病率为2.1%（95%CI：1.2 - 3.8%），研究间异质性较高（ = 1,055.2， = 99.1%， < 0.001）。SAS的合并患病率估计为23.5%（95%CI：18.6 - 29.3%），异质性也很显著（ = 1,019.3， = 98.4%， < 0.001）。不同的诊断工具或自我报告量表报告的SAD或SAS患病率存在显著差异。进一步按性别、年龄、抽样方法、经济状况和偏倚风险进行了分层分析。局限性包括研究间异质性水平高、研究数量不足以及测量导致的患病率显著差异。
https://www.crd.york.ac.uk/prospero/display_record.php?ID=CRD42020149591，标识符：PROSPERO CRD42020149591 。
